Abstract
Many different types of organisms use antimicrobial peptides, typically 20–40 amino acids in length, for defence against infection. Most are capable of rapidly killing a wide range of microbial cells. They have been classified according to their active structures into six extensive groups. It is not yet clear how these peptides kill bacterial cells, but it is widely believed that some cationic antimicrobial peptides kill by disrupting bacterial membranes, allowing the free exchange of intra- and extra-cellular ions. The selectivity of these peptides appears to relate to differences between the external membranes of prokaryotic and eukaryotic cells. The action of the peptides may involve the formation of ‘barrel-stave’ or ‘torroidal’ pores, the introduction of packing defects in the membrane phospholipids, or large-scale disruption of the membrane by a very dense aggregation of parallel-oriented peptide, called the ‘carpet mechanism’.
Antimicrobial peptides are attractive candidates for clinical development because of their selectivity, their speed of action and because bacteria may not easily develop resistance against them. Some antimicrobial peptides are already in clinical and commercial use, including ambicin (nisin), polymixin B and gramicidin S. There have been several attempts at developing peptides to make them more suitable for clinical use. For those peptides that act against bacterial membranes, it is possible to differentiate between those structural features that contribute to the specificity of initial membrane binding and those that contribute to the subsequent breach of membrane integrity. The design of novel antimicrobial peptides would necessitate the optimisation of multiple parameters, a problem that has proved difficult to solve.
Potential problems to be overcome include high production costs, toxicity against eukaryotic cells, susceptibility to proteolytic degradation and the development of allergies to the peptides. Biosynthesis, using recombinant DNA techniques, could make commercial-scale synthesis feasible but the peptides are usually lethal to the micro-organisms used to produce them. Proteolytic degradation can be reduced by modifying the peptides to contain nonstandard amino acids, or by restricting the use of peptides to topical applications. The problem of sensitisation could be overcome by the use of our own natural antibiotics to prevent or treat infections.
Despite early hopes that bacteria would not easily develop resistance to antimicrobial peptides, it is clear that some strains of bacteria already have.
Similar content being viewed by others
References
Epand RM, Vogel HJ. Diversity of antimicrobial peptides and their mechanisms of action. Biochim Biophys Acta 1999; 1462: 11–28
Peptaibol database [online]. Available from URL: http://www.public-1.cryst.bbk.ac.uk/peptaibol/welcome.html [Accessed 2003 Jun 12]
Zasloff M. Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc Natl Acad Sci U S A 1987; 84: 5549–53
Antimicrobial Sequences database [online]. Available from URL: http://bbc-ml.univ.trieste.it/~tossi/pagl.html [Accessed 2003 Jun 12]
Huang HW. Action of antimicrobial peptides: two-state model. Biochemistry 2000; 39: 8347–52
Ludtke SJ, He K, Wu Y, et al. Cooperative membrane insertion of magainin correlated with its cytolytic activity. Biochim Biophys Acta 1994; 1190: 181–4
Oren Z, Shai Y. Mode of action of linear amphipathic alpha-helical antimicrobial peptides. Biopolymers 1998; 47: 451–63
Vunnam S, Juvvadi P, Merrifield RB. Synthesis and antibacterial action of cecropin and proline-arginine-rich peptides from pig intestine. J Pept Res 1997; 49: 59–66
Hancock REW, Rozek A. Role of membranes in the activities of antimicrobial cationic peptides. FEMS Microbiol Lett 2002; 206: 143–9
Heller WT, Waring AJ, Lehrer RL, et al. Multiple states of beta-sheet peptide protegrin in lipid bilayers. Biochemistry 1998; 37: 17331–8
Matsuzaki K, Yoneyama S, Fujii N, et al. Membrane permeabilization mechanisms of a cyclic antimicrobial peptide, tachyplesin I, and its linear analog. Biochemistry 1997; 36: 9799–806
Cornet B, Bonmatin JM, Hetru C, et al. Refined 3-dimensional solution structure of insect defensin-A. Structure 1995; 3: 435–48
Kondejewski LH, Farmer SW, Wishhart D, et al. Modulation of structure and antibacterial and hemolytic activity by ring size in cyclic gramicidin S analogs. J Biol Chem 1996; 271: 25261–8
Märki F, Hänni E, Fredenhagen A, et al. Mode of action of the lanthionine-containing peptide antibiotics duramycin, duramycin-B and duramycin-C, and cinnamycin as indirect inhibitors of phospholipase-A2. Biochem Pharmacol 1991; 42: 2027–35
Thomas CJ, Surolia A. Kinetics of the interaction of endotoxin with polymyxin B and its analogs: a surface plasmon resonance analysis. FEBS Lett 1999; 445: 420–4
Vaara MJ. Increased outer-membrane resistance to ethylenediaminetetraacetate and cations in novel lipid A mutants. J Bacteriol 1981; 148: 426–34
Heiander IM, Kilpelainen I, Vaara M. Phosphate groups in lipopolysaccharides of Salmonella typhimurium rfaP mutants. FEBS Lett 1997; 409(3): 457–60
Guo L, Lim KB, Gunn JS, et al. Regulation of lipid A modifications by Salmonella typhimurium virulence genes phoP-phoQ. Science 1997; 276: 250–3
Hirakura Y, Kobayashi S, Matsuzaki K. Specific interactions of the antimicrobial peptidecyclic beta-sheet tachyplesin I with lipopolysaccharides. Biochim Biophys Acta 2002; 1562: 32–6
Ruhr E, Sahl HG. Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles. Antimicrob Agents Chemother 1985; 27: 841–5
Kazan K, Marcus JP, Goulter KC, et al. Application of genes encoding antimicrobial peptides for the control of fungal pathogens of canola [online]. Available from URL: http://www.regional.org.aU/au/gcirc/4/508.htm [Accessed 2003 Jun 12]
Dathe M, Wieprecht T. Structural features of helical antimicrobial peptides: their potential to modulate activity on model membranes and biological cells. Biochim Biophys Acta 1999; 1462: 71–87
Kondejewski LH, Jelokhani-Niaraki M, Farmer SW, et al. Dissociation of antimicrobial and hemolytic activities in cyclic peptide diastereomers by systematic alterations in amphipathicity. J Biol Chem 1999; 274: 13181–92
Micrologix Biotech Inc. [online]. Available from URL: http://www.mbiotech.com [Accessed 2003 Jun 12]
IntraBiotics Pharmaceuticals, Inc. [online]. Available from URL: http://www.intrabiotics.com/news/index.html [Accessed 2003 Jun 12]
Chen J, Falla TJ, Liu H, et al. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. Biopolymers 2000; 55: 88–98
Genaera Corporation [online]. Available from URL: http://www.genaera.com/infectiousdisease.html [Accessed 2003 Jun 12]
Izumiya N, Kato T, Aoyaga H, et al. Synthetic aspects of biologically active cyclic peptides: gramicidin S and tyrocidines. New York: Halstead Press, 1979
Gellman SH. Beta-amino acid oligomers with magainin-like activity [abstract]. Biophys J 2001; 80: 2d
Johnson DA, Yeh CK, Dodds MWJ. Effect of donor age on the concentrations of histatins in human parotid and submandibular/sublingual saliva. Arch Oral Biol 2000; 45: 731–40
Schröder J-M. Clinical significance of epithelial peptide antibiotics. BioDrugs 1999; 11: 293–300
Groisman EA, Parra-Lopez C, Salcedo M, et al. Resistance to host microbial peptides is necessary for Salmonella virulence. Proc Natl Acad Sci U S A 1992; 89: 11939–43
Guo L, Lim KB, Poduje CM, et al. Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides. Cell 1998; 95: 189–98
Banemann A, Deppisch H, Gross R. The lipopolysaccharide of Bordetella bronchiseptica acts as a protective shield against antimicrobial peptides. Infect Immun 1998; 66: 5607–12
Acknowledgements
The author has provided no information on sources of funding or on conflicts of interest directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bradshaw, J.P. Cationic Antimicrobial Peptides. BioDrugs 17, 233–240 (2003). https://doi.org/10.2165/00063030-200317040-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-200317040-00002